prikaz prve stranice dokumenta Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege
  Download
PDF 603.12 KB
Scientific paper - Original scientific paper
Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege
Liječnički vjesnik, 139 (2017), 5-6; 168-172. urn:nbn:hr:105:234188
Juretić, Antonio; Bašić-Koretić, Martina

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Juretić, A. & Bašić Koretić, M. (2017). Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege . Liječnički vjesnik, 139. (5-6), 168-172. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:234188

Juretić, Antonio and Martina Bašić Koretić. "Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege ." Liječnički vjesnik, vol. 139, no. 5-6, 2017, pp. 168-172. https://urn.nsk.hr/urn:nbn:hr:105:234188

Juretić, Antonio and Martina Bašić Koretić. "Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege ." Liječnički vjesnik 139, no. 5-6 (2017): 168-172. https://urn.nsk.hr/urn:nbn:hr:105:234188

Juretić, A. and Bašić Koretić, M. (2017) 'Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege ', Liječnički vjesnik, 139(5-6), pp. 168-172. Available at: https://urn.nsk.hr/urn:nbn:hr:105:234188 (Accessed 14 May 2024)

Juretić A, Bašić Koretić M. Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege . Liječnički vjesnik [Internet]. 2017 May [cited 2024 May 14];139(5-6):168-172. Available at: https://urn.nsk.hr/urn:nbn:hr:105:234188

A. Juretić and M. Bašić Koretić, "Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege ", Liječnički vjesnik, vol. 139, no. 5-6, pp. 168-172, May 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:234188. [Accessed: 14 May 2024]

Metadata
Title (croatian)Klinička imunoterapija raka blokadom molekularnih interakcija negativne povratne sprege
Title (english)Tumor immunotherapy in clinical setting based on the blockade of molecular interactions of the negative feedback mechanism
AuthorAntonio Juretić
AuthorMartina Bašić-Koretić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
The recent successful results of several relatively new immunotherapeutic anti-cancer strategies such as the blockade of immune inhibitory pathways by monoclonal antibodies against checkpoint molecules can be considered as a medical breakthrough in clinical cancer immunotherapy. This paper presents a basic overview of cancer immunoediting and the clinical application of monoclonal antibodies against checkpoint molecules in cancer patients. Interactions between the immune system and the malignancy are complex, but the results obtained by using the above mentioned therapeutic approaches indicate acceptable clinical utility, efficacy and safety against several types of cancer. Clinical application of monoclonal antibodies against checkpoint molecules CTLA-4, PD-1, and PD-L1, depending on which tumors these antibodies are tested and applied against, ranges from their already usage having been approved by regulatory agencies for patients with particular metastatic tumors to their testing in clinical studies with the aim of demonstrating their efficiency and consequently obtaining approval.
Abstract (croatian)
Nedavni uspješni rezultati više raznih novih imunoterapijskih pristupa u onkoloških bolesnika, kao, primjerice, blokada imunosnih inhibitornih molekularnih interakcija s monoklonskim protutijelima protiv molekula kontrolnih točaka, mogu se smatrati medicinskim iskorakom u kliničkoj onkologiji. Cilj je ovoga rada dati pojednostavnjeni prikaz imunosnog uređivanja raka i kliničke primjene monoklonskih protutijela protiv molekula kontrolnih točaka u onkoloških bolesnika. Interakcije između imunosnog sustava i autolognih tumora složene su, ali rezultati dobiveni primjenom monoklonskih protutijela protiv molekula kontrolnih točaka upućuju na prihvatljivu kliničku primjenjivost, učinkovitost i sigurnost u liječenju bolesnika s određenim tipovima raka. Klinička primjena monoklonskih protutijela protiv molekula kontrolnih točaka CTLA-4, PD-1 i PD-L1, ovisno o tome protiv kojih se tumora ta protutijela testiraju i primjenjuju, jest u rasponu od odobrenja regulatornih agencija i primjene u metastatskoj bolesti u bolesnika s određenim vrstama tumora pa do faza testiranja u kliničkim studijama, a radi istraživanja kliničke učinkovitosti i dobivanja odobrenja.
Languagecroatian
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleLiječnički vjesnik
Numberingvol. 139, no. 5-6, pp. 168-172
p-ISSN0024-3477
URN:NBNurn:nbn:hr:105:234188
Publication2017-05
Document URLhttps://hrcak.srce.hr/187276
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:41:11